Why Your Life Sciences Startup Needs a CXO - and How to Know Which One

A healthtech founder approached investors with a validated platform, a clear regulatory pathway, and a growing pipeline of interested NHS trusts. The conversations went well- until they did not.

Eighteen months in, no deals had closed. The platform was intact. Science had not changed.

What was missing was the commercial layer. No one owned the buyer journey. Financial projections were not investor-grade. Operations were held together by the founding team running at capacity.

This is not an unusual story. And the fix is no more science.

The Science-First Trap

Life sciences and biotech founders are, almost by definition, deep domain experts. That is the right starting point.

But as ZS research on emerging life sciences consistently shows, early-stage companies obsess over science while underinvesting in the commercial and operational layers that get a product to market.

Emerging life sciences companies often only obsess over science. Commercial leaders must add to that an obsession over patients, healthcare providers, payers, and investors.
Todd Wood, Chief Commercial Officer, emerging life sciences (via ZS)

Life sciences and biotech founders are, almost by definition, deep domain experts. That is the right starting point.

A Chief Commercial Officer brings the buyer's perspective into the room. A CFO builds the financial architecture that keeps investors engaged. A COO translates strategy into repeatable execution.

None of these functions happens reliably when they are one of twelve things a founder is managing simultaneously.

What the Numbers Say

Which CXO Do You Hire First? 

The answer depends entirely on where your biggest constraint sits.

A COO gives you the operational backbone to scale without the wheels coming off. Strategy without execution infrastructure is just a slide deck.

The title matters less than the function. And the function matters most when it is currently not owned by anyone.

Fractional First, Full-Time When Ready  

Not every startup needs a full-time C-suite hire from day one.

Fractional CXOs have become a legitimate and practical model in life sciences, giving early-stage companies access to senior leadership without the overhead of a permanent hire. The important thing is that the function is covered, the accountability is clear, and the founding team is freed to focus on what only they can do.

The strongest life sciences companies do not wait for a crisis to force the hire. They build their leadership layer as deliberately as they build their pipeline.